Abstract
Real-world treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A retrospective chart study.
Author
person
Xavier Guillaume
Cerner Enviza, Paris, France
info_outline
Xavier Guillaume, Dahbia Horchi, Jorge Gomez, Patrick Hlavacek, Jinma Ren, Alex Schepart, Didem Aydin, Marco DiBonaventura
Full text
Authors
person
Xavier Guillaume
Cerner Enviza, Paris, France
info_outline
Xavier Guillaume, Dahbia Horchi, Jorge Gomez, Patrick Hlavacek, Jinma Ren, Alex Schepart, Didem Aydin, Marco DiBonaventura
Organizations
Cerner Enviza, Paris, France, Pfizer Inc., New York, NY, Pfizer Inc., Collegeville, PA
Abstract Disclosures
Research Funding
Pharmaceutical/Biotech Company
Pfizer
Background:
Many patients with MM relapse or become refractory to various therapeutic approaches and typically cycle through many lines of treatment. The present study sought to understand how patients with TCR MM (ie, refractory to ≥1 PI, ≥1 IMiD, and ≥1 anti-CD38 therapy) are managed across various countries.
Methods:
A non-interventional, retrospective chart review study was conducted across the US, Canada (CA), the UK, France (FR), Germany (DE), Italy (IT), and Spain (ES). Oncologists/hematologists were recruited to abstract medical chart information into an electronic case report form from eligible MM patients (eg, refractory to ≥1 IMiD, ≥1 PI, and ≥1 anti-CD38 antibody treatment, ECOG≤2, and initiated their first therapy after their TCR status [ie, their index therapy] between 1/1/2018 and 12/31/2020 to ensure at least 1 year of follow-up). Abstractions were performed from January through April 2022. Demographics, clinical characteristics, and treatment patterns were descriptively analyzed and reported here.
Results:
N = 314 patients with TCR MM were included (56.7% male; median age = 70). Clinical characteristics were similar to other TCR MM studies (eg, 26.1% had an ECOG score of 2, 25.8% had high cytogenetic risk (ie, t(4:14), t(14:16), and/or del(17p), and 10.2% had extramedullary disease). Patients received a median of 3 treatment lines prior to their index therapy, with 70 unique treatment regimens reported as part of their index therapy line (Table 1). The most common regimens (> 10%) were Pd and Kd.
Conclusions:
This global chart review across the US, Canada, and Western Europe highlights the consistent lack of a standard of care for the management of MM among patients who are refractory to the three main classes of therapies.
Most common treatment regimens used immediately post-TCR across countries.
Overall
N = 314
CA
N = 21
FR
N = 67
DE
N = 27
IT
N = 55
ES
N = 46
UK
N = 65
US
N = 33
Pd
60 (19.1%)
5 (23.8%)
8 (11.9%)
11 (40.7%)
10 (18.2%)
7 (15.2%)
17 (26.2%)
2 (6.06%)
Kd
37 (11.8%)
1 (4.76%)
14 (20.9%)
4 (14.8%)
4 (7.27%)
12 (26.1%)
-
2 (6.06%)
Pd+Cy
29 (9.24%)
1 (4.76%)
4 (5.97%)
-
4 (7.27%)
15 (32.6%)
5 (7.69%)
-
RNd
16 (5.10%)
3 (14.3%)
1 (1.49%)
-
-
-
12 (18.5%)
-
EPd
13 (4.14%)
-
-
1 (3.70%)
3 (5.45%)
-
-
9 (27.3%)
Belantamab
11 (3.50%)
1 (4.76%)
1 (1.49%)
2 (7.41%)
3 (5.45%)
4 (8.70%)
-
-
Nd
10 (3.18%)
-
-
-
-
-
8 (12.3%)
2 (6.06%)
CAR-T
9 (2.87%)
-
4 (5.97%)
-
-
1 (2.17%)
-
4 (12.1%)
KPd
8 (2.55%)
-
4 (5.97%)
-
-
-
-
4 (12.1%)
P, pomalidomide; d, dexamethasone; K, carfilzomib; Cy, cyclophosphamide; R, lenalidomide; N, ixazomib; E, elotuzumab.
2 organizations
8 drugs
6 targets
Organization
Cerner EnvizaOrganization
Pfizer Inc., London, United KingdomDrug
dexamethasoneDrug
cyclophosphamideDrug
lenalidomideDrug
ixazomibTarget
SLAMF7Target
DexamethasoneTarget
ProteasomeTarget
CereblonTarget
DNATarget
BCMA×CD3